Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.43 |
| ▸ | CDK1 | P06493 | 9/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.43 |
| ▸ | NEK2 | P51955 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916480 | 0.90 | BRD4 (0.43) | PTK2BRD4JAK1JAK3 | |
| SCHEMBL4916505 | 0.87 | CDK2 (0.58) | CDK2CDK1CCNB2CCNB1CCNA2 | |
| SCHEMBL4920465 | 0.84 | TTK (0.51) | CDK2CDK1CCNB1PTK2BRD4 | |
| SCHEMBL4909020 | 0.82 | ADORA3 (0.48) | PTK2BRD4 | |
| SCHEMBL4917058 | 0.81 | PTK2 (0.47) | CDK1CCNB1NEK2PTK2KDR | |
| SCHEMBL4916898 | 0.80 | ADORA3 (0.45) | PTK2BRD4 | |
| SCHEMBL4917834 | 0.80 | NPC1 (0.46) | CDK2CDK1NEK2PTK2BRD4 | |
| SCHEMBL4649832 | 0.79 | PTK2 (0.50) | NEK2PTK2BRD4EPHB4JAK1 | |
| SCHEMBL4920060 | 0.78 | SCN9A (0.43) | CDK1PTK2KDRBRD4EPHB4 | |
| SCHEMBL4917022 | 0.78 | PIK3CA (0.46) | PTK2BRD4EPHB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | CDK2 252/4885CDK1 460/4885CCNB2 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.